PPARγ agonists have been shown to reduce blood glucose and insulin resistance, by comparing the effect of TNF-α in adipocytes, with potential therapeutic targets for obesity, dyslipidemia and diabetes. The gene discussed is TNF; the disease is obesity disorder.